期刊文献+

帕瑞昔布钠复合地佐辛预防全身麻醉苏醒期躁动的临床研究 被引量:6

暂未订购
导出
摘要 目的观察帕瑞昔布钠复合地佐辛预防全身麻醉苏醒期躁动的作用。方法全身麻醉下行择期甲状腺切除术患者120例随机均分为帕瑞昔布钠组(P组)、帕瑞昔布钠+地佐辛组(PD组)、地佐辛组(D组)和等容生理盐水组(C组)4组(n=30)。P组麻醉诱导前静注帕瑞昔布钠40 mg组、PD组麻醉诱导前静注帕瑞昔布钠40 mg并手术结束前30 min静注地佐辛0.1 mg/kg、D组手术结束前30 min静注地佐辛0.1 mg/kg,C组给予等容生理盐水。观察苏醒期躁动的发生情况。结果与C组比较,P、PD、D组苏醒期躁动发生显著减少(P<0.01),BCS分级和Ramsay评分更高(P<0.01),VAS评分更低(P<0.01);与P组和D组比较,PD组苏醒期躁动发生显著减少(P<0.05或0.01),BCS分级和Ramsay评分更高(P<0.05或0.01),VAS评分更低(P<0.05或0.01)。结论帕瑞昔布钠40 mg复合地佐辛0.1 mg/kg能更好地预防全身麻醉苏醒期躁动,有效提高苏醒期质量。 Objective To observe the effect of parecoxib combined dezocine on preventing agitation during wake-up from general anesthesia. Methods A total of 120 patients undergoing selective thyroidectomy under general anesthesia were randomly divided into 4 groups with 30 cases each. Group P received parecoxib 40 mg iv before induction of anesthesia, group PD received parecoxib 40 mg iv before induction of anesthesia plus dezocine 0.1 mg/kg iv 30 min before the end of operation, group D received dezocine 0.1 mg/kg iv 30 min before the end of operation,group C received equal volume of normal saline. The occurrence of agitation was observed during waking-up period in PACU. Results The rates of agitation was signiifcantly decreased in group s of P,PD and D than that in group of C ,The BCS and Ramsay values were higher and VAS values were lower than that in group of C. Conclusion Parecoxib 40 mg combined 0.1 mg/kg of dezocine can safely and effectively prevent the incidence of emergence agitation, so that to ensure the patients during analqesia period .
出处 《当代医学》 2014年第8期81-82,共2页 Contemporary Medicine
关键词 帕瑞昔布钠 地佐辛 苏醒期躁动 Parecoxib Dezocine Agitation during wake-up
  • 相关文献

参考文献9

二级参考文献33

  • 1徐国柱,李晓玲,段砺瑕,朱天岳,谢启伟,周应芳,王冰,邓艳萍,沈黎阳,袁旭.氟比洛芬酯脂微球载体注射液治疗中度术后疼痛的Ⅱ期临床试验[J].中国新药杂志,2004,13(9):846-848. 被引量:258
  • 2庄心良,曾因明,陈伯銮.现代麻醉学[M].北京:人民卫生出版社,2004∶ 7.
  • 3Moiniche S, Kehlet H, Dahl JB. Agualitative sys-tematic review of preenptive analgesia for postoperative pain relief: the role of analgesia [ J ]. Anesthesiology,2002,96 (4) :725-741.
  • 4Campistol JM, Sacks SH. Mechanisms of nephrotoxieity[ J ]. Transplan ration ,2006,69 (3) :555-560.
  • 5Reuben SS,Ekman EF, Raghunathan K,et al. The effect of yclooxygenase-2 inhibition on acute and chronic donor-site pain after spinalfusion surgery [ J]. Reg Anesth pain Med ,2006,31 ( 1 ) :6-13.
  • 6Rasmuseen GL, Steckner K, Hogue C, et al. Intravenous parecoxib sodium for acute pain after orthopedic knee surgery [ J]. Am J orthop ,2002,31 (2) :336-343.
  • 7Hubbard RC, Naumann TM, Traylor L, et al. Pareeoxib sodium has opioid-sparing effects in patients undergoing total knee arthroplasty under spinal anaesthesia[ J]. Br J Anaesth,2003,90( 1 ) :166-172.
  • 8Can TJ, Joshi GP, Zhao SZ, et al. Presurgical intravenous parecoxib sodium and follow-up oral valdecoxib for pain management after lap- aroseopic eholecystectomy surgery reduces opioid requirements and opioid-related adverse effects[J]. Acts Anaesthesiol Scand, 2004, 48(9) :1194-1212.
  • 9Robert J,Noveck MD, Richard C, et al. Parecoxib Sodium does not Impair Platelet Function in Healthy Elderly and Non-Elderly Individuals: Two Randomised, Controlled Trials [J]. Clin Drug Invest, 2001,21 (7) :465-476.
  • 10Dahl JB, Moniche S. Pre-emptive analgesia [ J ]. Br Med Bull, 2004,71( 1) : 13-27.

共引文献846

同被引文献50

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部